Orthopedic Surgery: Clinical Trials

3 completed, 1 recruiting, 1 withdrawn. 5 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	5	Completed 3, Recruiting 1, Withdrawn 1
Phase 2	2	Completed 2

Follow Orthopedic Surgery: new trials by email Literature Review of Orthopedic Surgery trials Research Report on Orthopedic Surgery

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Intraoperative Methadone for the Prevention of Postoperative Pain Methadone Hydrochloride, Sufentanil Citrate - Orthopedic Surgery	Phase 3	Recruiting	Brugmann University Hospital	80	2023-02-28	2025-02-07
Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients Melatonin 4 mg, Placebo oral tablet - Orthopedic Surgery	Phase 3	Completed	Assistance Publique - Hôpitaux de Paris	357	2021-01-23	2025-09-08
A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. epoetin alfa - Anemia, Blood Transfusion	Phase 3	Withdrawn	Janssen-Ortho Inc., Canada		1996-05-01	2016-09-20
A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery epoetin alfa - Blood Transfusion, Blood Transfusion, Autologous	Phase 2 / Phase 3	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	80	1990-01-01	2011-05-18
A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery. epoetin alfa - Blood Transfusion, Blood Transfusion, Autologous	Phase 2 / Phase 3	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	112		2011-05-18

Narrower conditions

Anemia (1)  ·  Delirium (1)

Broader conditions

Confusion (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Mental Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurobehavioral Manifestations (1)  ·  Neurocognitive Disorders (1)  ·  Neurologic Manifestations (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)

Interventions

Epoetin Alfa (3)  ·  Melatonin (1)  ·  Methadone (1)  ·  Sufentanil (1)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Brugmann University Hospital (1)  ·  Janssen-Ortho Inc., Canada (1)

Countries

Belgium (1)  ·  France (1)

Results publications

PMID 34952881